EGFR-Positive NSCLC: Treatment, Resistance, Progression & What Comes Next

Q: What does EGFR-positive lung cancer mean?

EGFR-positive lung cancer generally means that testing has identified a clinically relevant alteration in the EGFR gene. The exact alteration matters because different EGFR variants can have different treatment implications.

Q: How long does osimertinib work?

Duration of benefit varies between individuals. Resistance can eventually develop, but the timing and mechanism are not identical for every patient.

Q: Can ivermectin, mebendazole or fenbendazole treat EGFR-positive NSCLC?

There is insufficient clinical evidence to establish these drugs as standard treatments for EGFR-positive NSCLC. Preclinical findings and patient reports can generate hypotheses but cannot establish efficacy.

Q: What should I do if my cancer progresses on targeted therapy?

Progression should first be confirmed and characterized. Depending on the individual situation, the oncology team may consider molecular reassessment, tissue biopsy, CNS assessment, local therapy, mechanism-directed treatment, chemotherapy or a clinical trial.

EGFR-Positive NSCLC: Treatment, Resistance, Progression & What Comes Next

OneDayMD Cancer Academy

A patient-first guide to EGFR-mutated non-small cell lung cancer (NSCLC), targeted therapy, treatment response, acquired resistance, progression, biomarker retesting, brain metastases, and treatment options after resistance.

The most important idea: EGFR-positive lung cancer is not one static disease. The molecular profile of a tumor can change over time, particularly when treatment creates evolutionary pressure. When cancer progresses, the next question is often not simply “What drug should I take?” but “What has changed biologically, and what evidence do we have?”

This Academy page is designed to help patients and families understand the logic of modern precision oncology and prepare better questions for their oncology team. It does not replace individualized medical care.

Start With the Seven Questions Every EGFR Patient Should Ask

1What exactly is my cancer?

Is it NSCLC? What histologic subtype? What stage? Where has it spread? Is the diagnosis based on tissue pathology?

2What is my biomarker?

Which EGFR alteration is present? Exon 19 deletion, L858R, exon 20 insertion, or another EGFR alteration?

3What treatment am I receiving?

Is the treatment targeted therapy, chemotherapy, immunotherapy, radiation, surgery, or a combination?

4Is the treatment working?

What do imaging, symptoms, tumor markers when relevant, and molecular tests actually show?

5If the cancer progresses, why?

Could progression reflect an acquired resistance mutation, bypass pathway, histologic transformation, CNS progression, or another mechanism?

6Should the tumor be retested?

Would tissue biopsy, liquid biopsy, ctDNA, or repeat next-generation sequencing help identify a potentially actionable resistance mechanism?

7What are my next evidence-based options?

Are there approved therapies, local treatments, clinical trials, or other evidence-supported strategies appropriate for the new disease state?

The EGFR Patient Journey

The pathway below is deliberately designed as a series of mobile-friendly entry points. A patient does not have to read the entire Academy in one sitting. Start at the stage that matches your current situation.

STEP 1 New diagnosis

Understand pathology, stage, EGFR testing and what the diagnosis means.

Start here →

STEP 2 Starting treatment

Understand targeted therapy and how response is monitored.

Treatment guide →

STEP 3 Stable or responding

Understand surveillance, residual disease and why resistance can eventually occur.

Monitoring →

STEP 4 Possible progression

Determine whether progression is systemic, oligoprogressive or CNS-predominant.

Progression →

STEP 5 Resistance

Look for an acquired molecular or biological explanation.

Resistance →

STEP 6 Retesting

Review tissue biopsy, liquid biopsy, ctDNA and repeat molecular profiling.

Retesting →

STEP 7 Next treatment

Compare approved treatments, local therapies and clinical-trial opportunities.

Next steps →

STEP 8 Long-term care

Integrate symptom control, supportive care, nutrition, activity and survivorship.

Support →

1. What Does EGFR-Positive NSCLC Mean?

Non-small cell lung cancer is a group of lung cancers with different histologies, molecular drivers and treatment responses. In a subset of patients, tumor cells carry an activating alteration in the EGFR gene.

EGFR stands for epidermal growth factor receptor. Certain EGFR alterations can cause persistent signaling through pathways that promote cell proliferation and survival.

The clinical importance is that some EGFR alterations are actionable biomarkers: they can identify patients who may benefit from therapies designed to inhibit EGFR signaling.

Patient takeaway: “EGFR-positive” does not by itself tell you the stage, prognosis, treatment, or resistance pattern. The exact EGFR alteration, disease extent, previous treatment and current molecular profile all matter.

2. EGFR Mutations: The Biomarker Comes First

A precision-oncology approach begins by defining the molecular alteration as accurately as possible. Common sensitizing EGFR alterations include exon 19 deletions and L858R, while other alterations can have different therapeutic implications.

Common EGFR categories

Exon 19 deletions

A common sensitizing EGFR alteration. Treatment decisions depend on the individual clinical context and current treatment guidelines.

L858R

Another common sensitizing EGFR alteration that can guide targeted treatment.

Exon 20 insertions

A distinct molecular category. These alterations should not automatically be treated as biologically equivalent to exon 19 deletion or L858R.

Uncommon EGFR alterations

Some uncommon variants have different levels of sensitivity to available EGFR-directed therapies. Interpretation should be mutation-specific.

What should be in the molecular report?

Exact EGFR variant or alteration.
Testing method and laboratory.
Whether the result came from tissue or blood.
Other potentially actionable alterations.
PD-L1 status where clinically relevant.
Any reported copy-number changes or resistance alterations.

Important: A negative blood-based test does not necessarily prove that the tumor lacks a mutation. The amount of circulating tumor DNA can vary substantially. Clinical teams may consider tissue testing when the clinical situation warrants it.

3. First-Line Treatment: Target the Driver

For advanced EGFR-mutated NSCLC, EGFR-targeted therapy has fundamentally changed the treatment paradigm. The appropriate treatment depends on the specific EGFR alteration, disease extent, patient characteristics, prior therapy and current guidelines.

Osimertinib / Tagrisso

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor widely used in EGFR-mutated NSCLC. It is designed to inhibit sensitizing EGFR alterations and the T790M resistance alteration, and has important CNS activity.

However, the presence of an effective targeted therapy does not mean that resistance cannot occur. Cancer populations evolve under treatment pressure.

The key concept

Response is not the same as cure. A targeted therapy can produce substantial tumor control while resistant subclones remain or emerge over time. This is one reason longitudinal molecular monitoring becomes important when disease changes.

4. How Do We Know Whether Treatment Is Working?

Treatment response is usually assessed using a combination of clinical, radiological and, in selected situations, molecular information.

Imaging

CT and, when appropriate, PET or MRI provide anatomical or functional information about disease burden.

Symptoms

Breathlessness, cough, pain, neurological symptoms, weight changes and functional status can provide important clinical context.

Molecular monitoring

ctDNA and other molecular tests may provide additional information in selected patients, but they do not replace clinical assessment or imaging.

Response categories should not be oversimplified

Response: measurable disease decreases according to the assessment method.
Stable disease: disease does not meet criteria for meaningful response or progression.
Progression: disease meets accepted criteria for growth or new disease.
Mixed response: some lesions improve while others grow.
CNS progression: disease changes primarily or exclusively in the brain or CNS.

5. Why Does EGFR Therapy Eventually Stop Working?

Cancer is an evolving population of cells rather than a genetically uniform block of tissue. Treatment can eliminate sensitive cells while allowing pre-existing or newly acquired resistant populations to become dominant.

This process is often described as clonal evolution.

On-target resistance

The EGFR target itself changes so that the drug binds less effectively.

Bypass signaling

Cancer cells activate another pathway that restores downstream growth signaling despite EGFR inhibition.

Phenotypic transformation

The tumor can change its cellular phenotype, creating a biologically different disease state.

CNS sanctuary/progression

Disease can evolve in the brain or CNS where drug exposure, tumor biology and the blood-brain barrier create special treatment challenges.

Resistance is information. Progression should ideally trigger a search for the biological explanation, not simply an automatic switch to an unrelated treatment.

6. Major EGFR Resistance Mechanisms

The resistance landscape is heterogeneous. A patient may have one dominant mechanism, multiple mechanisms, or a mechanism that remains undetected.

EGFR C797S

A classic on-target resistance alteration associated with covalent EGFR inhibitors. Its therapeutic implications depend partly on the configuration of other EGFR mutations.

Explore C797S →

MET amplification

Activation of the MET pathway can provide bypass signaling that reduces dependence on EGFR inhibition.

Explore MET →

HER2 and other bypass pathways

Alternative receptor tyrosine kinase signaling can restore downstream pro-survival pathways.

Histologic transformation

In selected cases, the tumor can undergo transformation into a different histologic phenotype, changing treatment considerations.

Explore transformation →

7. EGFR C797S: Why This Mutation Matters

C797 is an important binding site for covalent third-generation EGFR inhibitors. A substitution such as C797S can interfere with covalent drug binding and contribute to resistance.

C797S is not one single clinical scenario

The significance of C797S depends on the broader EGFR genotype. In particular, the relationship between C797S and other EGFR mutations can influence whether different generations or combinations of EGFR-directed strategies might retain activity.

Do not interpret C797S in isolation. A molecular report should be reviewed as a complete genotype rather than treating one mutation as a stand-alone diagnosis.

Research direction

Next-generation EGFR inhibitors and rational combinations are being investigated to address resistant EGFR configurations. Availability and evidence vary by country, mutation and clinical-trial setting.

8. MET Amplification: A Bypass Resistance Pathway

MET amplification is one of the best-known bypass mechanisms associated with resistance to EGFR-directed therapy.

Conceptually, the tumor may remain dependent on downstream signaling through pathways such as PI3K/AKT and MAPK even when EGFR is inhibited. Increasing MET signaling can provide an alternative route into those downstream networks.

Why MET testing matters

It may explain progression despite continued EGFR inhibition.
It can identify a potentially targetable biological pathway.
It can influence clinical-trial eligibility.
It reinforces why repeat molecular profiling can be useful after progression.

When MET-driven resistance is suspected, treatment decisions should be based on validated testing and the current evidence for EGFR/MET combination strategies.

9. Histologic Transformation

Not all resistance is explained by a new DNA mutation. In some patients, the tumor undergoes a biological transformation into another histologic phenotype.

One important example in EGFR-mutated lung cancer is transformation toward small-cell lung cancer. Such transformation can alter treatment sensitivity and may require a fundamentally different therapeutic strategy.

Why tissue can matter: Liquid biopsy can identify circulating molecular alterations, but it cannot always reveal a histologic transformation. When clinically appropriate, a tissue biopsy can provide information that blood testing cannot.

10. Progression: Not All Progression Is the Same

A major patient-management distinction is whether progression is widespread or limited to a small number of sites.

Systemic progression

Multiple sites show convincing progression. The overall treatment strategy may need to change.

Oligoprogression

Only a limited number of lesions progress while most disease remains controlled. Local treatment may sometimes be considered alongside continuation or adjustment of systemic therapy.

CNS-only progression

Progression is primarily or exclusively detected in the brain or CNS. Management requires specific CNS assessment.

Mixed response

Some lesions respond while others grow. This pattern can suggest heterogeneous tumor biology and may justify additional investigation.

One scan does not tell the whole story

When progression appears limited or unexpected, clinicians may consider the pattern, timing, symptoms, previous response, treatment adherence, imaging quality and molecular evidence before deciding what comes next.

11. EGFR-Positive NSCLC and Brain Metastases

The CNS is a special therapeutic environment because the blood-brain barrier can influence drug distribution. EGFR-mutated NSCLC also has a clinically important propensity for CNS involvement.

Questions to ask when CNS disease is suspected

Has brain MRI been performed when clinically indicated?
Are there neurological symptoms?
Is the CNS disease new, stable or progressing?
Is the systemic disease controlled?
Is local therapy such as stereotactic radiation appropriate?
Does the systemic therapy have meaningful CNS activity?

Management can involve systemic targeted therapy, stereotactic radiation, surgery in selected cases, whole-brain radiation in selected circumstances, or combinations of these approaches.

The correct approach depends heavily on lesion number, size, location, symptoms, prior radiation and systemic disease status.

12. Retesting After Progression: Tissue, Blood or Both?

When EGFR-targeted therapy stops controlling disease, molecular reassessment may provide critical information.

Tissue biopsy

Can provide DNA/RNA information and, importantly, histology. It may be valuable when transformation is suspected.

Liquid biopsy

Blood-based circulating tumor DNA testing can be less invasive and may identify some resistance alterations.

Repeat NGS

Broad next-generation sequencing may identify an acquired alteration that was not present or not detectable at initial diagnosis.

Why a negative liquid biopsy can be difficult to interpret

Circulating tumor DNA shedding varies by tumor site, burden and biology. A negative blood result therefore does not necessarily exclude a resistance alteration.

Practical principle: If a potentially actionable resistance mechanism is strongly suspected but blood testing is unrevealing, the oncology team may consider whether tissue re-biopsy is clinically feasible and useful.

13. What Happens After EGFR-Targeted Therapy Progresses?

There is no universal “second-line EGFR treatment.” The correct next step depends on the mechanism and pattern of progression.

A practical decision sequence

Confirm progression.
Characterize the pattern: systemic, oligoprogressive, mixed or CNS.
Review previous treatment and response.
Perform appropriate molecular reassessment.
Look for an actionable resistance mechanism.
Consider local treatment when appropriate.
Evaluate approved systemic therapies.
Consider clinical trials.
Integrate supportive and palliative care throughout.

Potential treatment categories

Mechanism-directed therapy

When an actionable resistance mechanism is identified, a matched therapy may be considered if an appropriate approved or trial option exists.

Chemotherapy

Platinum-based or other chemotherapy strategies remain important options in advanced NSCLC depending on prior treatment and clinical context.

Antibody-drug conjugates

ADCs represent an expanding therapeutic class in lung cancer. Their use depends on the relevant target, regulatory approval and clinical setting.

Clinical trials

Trials can provide access to investigational therapies specifically designed for resistance mechanisms that lack established treatment.

Do not stop an effective targeted therapy without medical guidance. Treatment changes should be coordinated with the treating oncology team, especially when progression is limited or uncertain.

14. EGFR-Mutated NSCLC and Immunotherapy

Immunotherapy has transformed treatment for many forms of NSCLC, but EGFR-mutated disease presents a more complex therapeutic context.

PD-L1 expression alone does not necessarily determine the optimal treatment sequence for a patient with an actionable EGFR driver.

Why molecular context matters

EGFR-mutated tumors represent a biologically distinct subgroup.
Targeted therapy may have a different risk-benefit profile from immunotherapy.
Prior or subsequent treatment sequencing can matter.
CNS disease can change the therapeutic priority.
Clinical trials may investigate rational combinations or new sequencing strategies.

15. Clinical Trials: The Option Patients Often Underuse

Clinical trials are particularly important when standard treatment options are limited or when a tumor contains a rare resistance mechanism.

Trial categories relevant to EGFR resistance may include

Next-generation EGFR inhibitors.
Fourth-generation or mutation-specific EGFR inhibitors.
EGFR/MET combination strategies.
Antibody-drug conjugates.
Bispecific antibodies.
Novel CNS-penetrant therapies.
Combination strategies designed to prevent or overcome resistance.

Clinical-trial principle: A trial is not automatically “better” than standard treatment. It is an evidence-generating option whose suitability depends on eligibility, potential benefit, risks, alternatives and patient preference.

16. Repurposed Drugs: Where Do Ivermectin, Mebendazole and Fenbendazole Fit?

OneDayMD has published extensive material on repurposed drugs in oncology. Because these subjects are frequently discussed by patients with advanced or treatment-resistant cancer, Cancer Academy deliberately places them inside an evidence hierarchy rather than presenting them as established EGFR treatments.

E0 Established clinical standard

Guideline-supported care with substantial clinical evidence.

E1 Strong clinical evidence

High-quality human evidence, but applicability may depend on context.

E2 Moderate / emerging clinical evidence

Human studies exist but limitations remain.

E3 Early or limited human evidence

Small studies, observational evidence or early clinical signals.

E4 Preclinical evidence

Cell, animal or mechanistic evidence without adequate clinical validation.

E5 Hypothesis / anecdotal evidence

Case reports, testimonials, theoretical combinations or computational models.

Ivermectin

Ivermectin has generated substantial laboratory interest in cancer biology, including proposed effects on signaling pathways and cell survival. However, preclinical activity does not establish clinical efficacy in EGFR-mutated NSCLC.

Mebendazole

Mebendazole has been investigated experimentally in several cancers, with preclinical evidence involving microtubules, angiogenesis and other pathways. Clinical evidence remains insufficient to establish it as a standard treatment for EGFR-positive NSCLC.

Fenbendazole

Fenbendazole is primarily a veterinary antiparasitic. Anticancer interest is based largely on preclinical research and patient-reported cases rather than established randomized clinical evidence.

Critical distinction: None of these agents should be presented as proven substitutes for EGFR-targeted therapy, chemotherapy, radiation, surgery or other evidence-based cancer care. Case reports cannot determine whether an intervention caused tumor regression, because patients often receive multiple treatments simultaneously and spontaneous or treatment-associated changes can have many explanations.

17. Systems Oncology: Looking Beyond the Mutation

Precision oncology begins with molecular drivers, but cancer biology does not stop at DNA sequence.

Tumor evolution involves interactions among genetic alterations, epigenetic state, metabolism, immune surveillance, stromal cells, hypoxia, angiogenesis and treatment exposure.

This broader perspective can be useful when thinking about resistance. However, a systems framework should complement—not replace—evidence-based oncology.

Tumor genetics

Driver mutations, resistance mutations and clonal evolution.

Immune environment

T-cell function, immune suppression and inflammatory signaling.

Metabolism

Energy utilization, glucose metabolism and systemic metabolic health.

Microenvironment

Stroma, hypoxia, extracellular matrix, angiogenesis and cellular interactions.

18. Supportive Care Is Part of Cancer Care

Precision oncology is not only about selecting an anticancer drug. Patients also need symptom control, nutrition assessment, physical activity when appropriate, psychological support, sleep, medication review and management of treatment-related adverse effects.

Questions worth discussing with the care team

Am I maintaining adequate nutrition and muscle mass?
What symptoms should trigger an urgent call?
How should fatigue or breathlessness be managed?
What exercise is appropriate for my current condition?
Could any supplement interact with my cancer treatment?
Should I see a dietitian, physiotherapist, pharmacist or palliative-care specialist?

Palliative care is not the same as giving up. Specialist palliative care can be integrated with active cancer treatment and focuses on symptoms, function, quality of life and support for patients and families.

19. The Cancer Academy: 10 Schools

This EGFR pillar sits within the larger OneDayMD Cancer Academy architecture. The Academy is designed around the questions patients actually ask rather than around isolated medical specialties.

Cancer Biology School

Understand how cancer develops, evolves, spreads and becomes resistant.

Diagnosis & Staging School

Pathology, imaging, staging, biopsy and molecular diagnosis.

Precision Oncology School

Genomics, biomarkers, targeted therapy and personalized treatment.

Treatment School

Surgery, radiation, chemotherapy, targeted therapy and immunotherapy.

Resistance School

Why treatment stops working and how resistance can be investigated.

Metabolic & Immune Health School

Metabolism, inflammation, immunity, nutrition and host biology.

Integrative Oncology School

Evidence-based supportive and complementary approaches.

Clinical Trials School

How experimental therapies are tested and how patients can evaluate trials.

Survivorship School

Long-term monitoring, recurrence risk, function and quality of life.

Patient Intelligence School

How to read reports, compare evidence and ask better oncology questions.

20. The Cancer Academy Knowledge Architecture

The Academy's underlying information architecture is built around four linked dimensions:

Cancer type

Lung, breast, colorectal, prostate, pancreatic, brain, hematologic and other cancers.

Biomarker

EGFR, ALK, ROS1, KRAS, BRAF, HER2, BRCA, MSI-H, TMB, PD-L1 and emerging biomarkers.

Treatment

Targeted therapy, immunotherapy, chemotherapy, radiation, surgery, ADCs and clinical trials.

Resistance

On-target mutations, bypass signaling, transformation, immune resistance, metabolic adaptation and CNS progression.

This architecture allows a patient to enter through a cancer diagnosis, a biomarker, a treatment or a resistance mechanism and still reach the same underlying knowledge graph.

21. The EGFR Patient Decision Framework

When facing a major treatment decision, use this sequence to organize the conversation with your oncology team.

1. Disease state

Stage?
Sites of disease?
Symptoms?
CNS involvement?

2. Molecular state

EGFR alteration?
Other actionable variants?
Resistance mutation?
Transformation?

3. Treatment state

Current treatment?
Previous treatment?
Duration of response?
Toxicities?

4. Evidence state

Approved treatment?
Clinical trial?
Early clinical evidence?
Preclinical only?

The four-question checkpoint

What changed?
Why might it have changed?
Can we test that explanation?
What options match the evidence?

22. Cancer Academy Patient Tools Roadmap

The Cancer Academy will progressively add interactive tools designed to turn complex oncology information into patient-friendly decision support.

Cancer Treatment Selector

Map cancer type, stage, biomarker and treatment history to questions for the oncology team.

Roadmap

Biomarker Interpreter

Explain common molecular terms and identify questions for molecular tumor boards.

Roadmap

Resistance Explorer

Start with the treatment that stopped working and explore possible resistance mechanisms.

Roadmap

Clinical Trial Navigator

Help patients understand eligibility criteria and questions to ask before considering a trial.

Roadmap

Second-Opinion Checklist

Generate a structured list of pathology, imaging, molecular and treatment documents to bring to another oncology consultation.

Roadmap

Evidence Grader

Classify a proposed cancer intervention from established clinical evidence through preclinical and hypothesis-level evidence.

Roadmap

23. OneDayMD Cancer Academy Evidence Standards

Cancer information is especially vulnerable to overstatement. The Academy therefore uses an explicit evidence hierarchy.

E0 — Standard of care

Established clinical practice supported by authoritative guidelines and substantial clinical evidence.

E1 — High-quality clinical evidence

Strong randomized or otherwise robust human evidence relevant to the question.

E2 — Moderate clinical evidence

Human evidence exists but may be limited by sample size, design, consistency or applicability.

E3 — Early human evidence

Small trials, observational studies or preliminary clinical signals.

E4 — Preclinical

Cellular, animal, pharmacological or mechanistic evidence.

E5 — Hypothesis / anecdote

Testimonials, case compilations, theoretical combinations, computational models or other evidence unable to establish clinical efficacy.

What the Academy does not do

It does not turn laboratory findings into proven treatments.
It does not treat testimonials as randomized evidence.
It does not imply that “natural” means safe.
It does not present experimental drugs as substitutes for standard care.
It does not claim that an association proves causation.
It does not promise cancer cures or individual outcomes.

24. Editorial & E-E-A-T Standards

The OneDayMD Cancer Academy is intended to function as an educational cancer intelligence resource with transparent evidence labeling.

Our editorial principles

Patient-first language.
Clear separation between evidence and hypothesis.
Preference for peer-reviewed clinical evidence.
Use of authoritative oncology guidelines where applicable.
Disclosure when evidence is preclinical or anecdotal.
Transparent discussion of uncertainty.
Clear distinction between education and medical advice.
Regular updating as oncology evidence evolves.

Important: An evidence grade is not a recommendation. A treatment can have interesting biology but still lack enough clinical evidence for routine use. Conversely, a supportive-care intervention can have a favorable evidence and risk profile without being an anticancer treatment.

25. Explore the OneDayMD Cancer Knowledge Network

26. Future EGFR Cluster Pages

This master page is designed to become the hub for a future series of focused articles. Each future article should link back to this pillar.

EGFR Exon 19 Deletion

Biology, treatment and resistance.

EGFR L858R

What the mutation means and treatment considerations.

EGFR Exon 20 Insertion

A separate molecular pathway and therapeutic landscape.

Osimertinib / Tagrisso

Mechanism, efficacy, CNS activity and resistance.

C797S

On-target resistance after third-generation EGFR therapy.

MET Amplification

Bypass resistance and EGFR/MET strategies.

EGFR Brain Metastases

CNS disease, imaging and treatment strategies.

Liquid Biopsy & ctDNA

When blood testing can and cannot identify resistance.

EGFR Treatment After Progression

How the next treatment decision is constructed.

EGFR Clinical Trials

Emerging therapies and trial interpretation.

27. Frequently Asked Questions

What does EGFR-positive lung cancer mean?

It generally means that testing has identified an activating or otherwise clinically relevant alteration in the EGFR gene. The exact alteration matters because different EGFR variants can have different treatment implications.

Is EGFR-positive lung cancer curable?

The answer depends on stage, disease biology and treatment response. Some localized EGFR-positive cancers can be treated with curative intent, while advanced disease is generally managed as a chronic but potentially serious condition with systemic treatment. Individual prognosis cannot be determined from EGFR status alone.

How long does osimertinib work?

Duration of benefit varies substantially between individuals. Resistance can eventually develop, but the timing and mechanism are not identical for every patient.

What is the most common reason Tagrisso stops working?

There is no single resistance mechanism that explains every patient. Resistance can involve EGFR itself, bypass pathways such as MET, histologic transformation, CNS progression and other biological changes.

What is C797S?

C797S is an EGFR alteration that can interfere with covalent binding of certain third-generation EGFR inhibitors. Its clinical significance depends on the complete EGFR genotype and treatment history.

What is MET amplification?

MET amplification is an increase in MET gene copy number that can activate bypass signaling and contribute to resistance to EGFR-directed treatment.

Should I have another biopsy when EGFR treatment stops working?

It may be appropriate in selected situations. A repeat biopsy can identify acquired molecular alterations and can also reveal histologic transformation. Whether it is worthwhile depends on disease location, procedural risk and the clinical question.

Can a liquid biopsy replace a tissue biopsy?

Not always. Liquid biopsy is less invasive and can detect circulating tumor DNA, but sensitivity varies. Tissue can also provide histologic information that blood testing cannot.

Can EGFR-positive lung cancer be treated with immunotherapy?

Immunotherapy can have a role in lung cancer, but EGFR-mutated NSCLC requires careful treatment sequencing and molecular context. PD-L1 status should not be interpreted in isolation from the actionable EGFR driver and treatment history.

Can ivermectin, mebendazole or fenbendazole treat EGFR-positive NSCLC?

There is currently insufficient clinical evidence to establish these drugs as standard treatments for EGFR-positive NSCLC. Preclinical findings and patient reports can generate hypotheses but cannot establish efficacy. They should not be substituted for evidence-based cancer treatment.

What should I do if my cancer progresses on targeted therapy?

First confirm the progression and characterize its pattern. Then discuss whether repeat molecular testing, tissue biopsy, CNS assessment, local therapy, mechanism-directed treatment, chemotherapy or a clinical trial is appropriate.

Is oligoprogression different from widespread progression?

Yes. Oligoprogression refers to progression in a limited number of sites while other disease remains controlled. In selected patients, local treatment of progressing lesions may be considered while systemic treatment is continued or modified.

Why are clinical trials important in EGFR resistance?

Some resistance mechanisms have no established targeted treatment. Clinical trials allow investigators to test new drugs and combinations while generating evidence for future care.

28. Take This Checklist to Your Oncology Appointment

What is the exact histologic diagnosis?
What is my current stage?
What exact EGFR alteration do I have?
What other biomarkers have been tested?
What is my current treatment and its goal?
How are we measuring response?
If progression occurs, where is it?
Could this be oligoprogression or CNS-only progression?
Should I have tissue biopsy?
Would liquid biopsy or ctDNA add information?
Should repeat NGS be performed?
Is there an identifiable resistance mechanism?
Are there approved treatments for that mechanism?
Are there relevant clinical trials?
What are the expected benefits and risks of each option?
What symptoms should prompt urgent medical attention?

29. Bottom Line

EGFR-positive NSCLC is a moving biological target.

The modern approach is not simply: diagnosis → drug → progression → another drug.

A more useful framework is:

Diagnosis → Biomarker → Treatment → Response → Resistance → Retesting → Matched Next Step

When progression occurs, the most valuable information may be the explanation for progression. Molecular reassessment, CNS evaluation, tissue pathology, local treatment and clinical trials can all become important depending on the individual situation.

The goal of Cancer Academy is to make this complex process understandable without overstating what medical science currently knows.

30. About This Cancer Academy Page

This page is part of the OneDayMD Cancer Academy, an educational initiative designed to organize complex cancer information around the questions patients and families face during diagnosis, treatment and progression.

The page is intended to evolve as evidence changes. Sections may be expanded into dedicated cluster articles, evidence reviews, biomarker explainers and patient decision tools.

Last reviewed: August 2026.

Medical Disclaimer

This Cancer Academy page is for educational and informational purposes only. It is not medical advice, diagnosis or a substitute for care from a qualified oncologist or other healthcare professional.

Cancer treatment decisions are highly individualized. Treatment availability, regulatory approvals, clinical guidelines and evidence can change over time and vary between countries.

Do not start, stop or change a cancer treatment, prescription medicine, supplement or experimental therapy based solely on information presented here. Discuss treatment decisions with your oncology team.

Experimental, repurposed and investigational therapies discussed on OneDayMD should not be interpreted as proven cancer treatments unless the page explicitly states that adequate clinical evidence supports that conclusion.